DelveInsight’s, “Wet AMD Pipeline Insight, 2025” report provides comprehensive insights about 60+ companies and 70+ pipeline drugs in the Wet-AMD pipeline landscape. It covers the Wet AMD pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Wet AMD pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Wet AMD Pipeline. Dive into DelveInsight’s comprehensive report today! @ Wet AMD Pipeline Outlook

Key Takeaways from the Wet AMD Pipeline Report

• In July 2025, Novartis Pharmaceuticals announced a study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD.
• In July 2025, Innostellar Biotherapeutics Co Ltd conducted a study is to evaluate the overall safety and efficacy of LX102 gene therapy for nAMD.
• DelveInsight’s Wet AMD Pipeline report depicts a robust space with 60+ active players working to develop 60+ pipeline therapies for Wet AMD treatment.
• The leading Wet AMD Companies such as Outlook Therapeutics, Opthea, Sylentis, Boehringer Ingelheim, Molecular Partners, Sam Chun Dang Pharm, Generium, Alvotech, Adverum Biotechnologies, EyePoint Pharmaceuticals, 4D Molecular Therapeutics, OliX Pharmaceuticals, Kyowa Kirin, Exonate and others.
• Promising Wet AMD Pipeline Therapies such as NT-101 0.05 mM, Eylea® (Aflibercept), Intravitreal aflibercept injection, RGX-314, ABP 938, Aflibercept, Ixo-vec, Ranibizumab, and others.

Stay ahead with the most recent pipeline outlook for Wet AMD. Get insights into clinical trials, emerging therapies, and leading companies with Wet AMD @ Wet AMD Treatment Drugs

Wet AMD Emerging Drugs Profile

• ONS-5010: Outlook Therapeutics

ONS-5010 / LYTENAVA™ (bevacizumab-vikg) is an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet AMD and other approved retinal diseases. Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. Following intravitreal injection the binding of bevacizumab-vikg to VEGF prevents the interaction of VEGF with its receptors on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation in the retina. Currently the drug is been registered for the treatment of Wet Age-Related Macular Degeneration (Wet-AMD).

• OPT-302: Opthea

OPT-302 is a soluble form of vascular endothelial growth factor receptor (VEGFR)-3 expressed as an immunoglobulin G1 (IgG1) Fc-fusion protein. It binds and neutralizes the activity of vascular endothelial growth factor (VEGF)-C and VEGF-D on their endogenous receptors, VEGFR-2 and VEGFR-3. Targeted inhibition of VEGF-C and VEGF-D can prevent blood vessel growth and vascular leakage, which contribute to the pathophysiology of retinal diseases including neovascular “wet” AMD. It is a first-in-class intravitreally administered biologic “trap” inhibitor of vascular endothelial growth factors C (VEGF-C) and D (VEGF-D) currently being investigated in two concurrent Phase III pivotal registrational trials that will each enroll ~990 treatment naïve patients, in combination with two approved anti-VEGF-A treatments, ranibizumab (ShORe trial) and aflibercept (COAST trial). OPT-302 has the potential to be positioned as complementary and agnostic with any combined anti–VEGF-A therapy for the treatment of wet AMD, a strategy intended to maximize the commercial opportunity for the therapy. Currently the drug in in Phase III stage of its treatment of Wet Age-Related Macular Degeneration (Wet-AMD).

• SYL1801: Sylentis

SYL1801 is a small interfering RNA (siRNA) in the non-clinical research phase. This siRNA, by means of mechanism of action based on RNA interference (RNAi), inhibits the synthesis of NRARP (Notch-regulated ankyrin repeat-containing protein). NRARP is directly involved in the pathophysiology of choroidal neovascularization, i.e. the abnormal formation of new vessels from the choroid into the retina. It is a common hallmark of several retinal diseases such as age-related macular degeneration (AMD) or diabetic retinopathy (DR). During angiogenesis (new vessel formation), NRARP integrates the Notch and Wnt signaling pathways by controlling stalk cell proliferation to stabilize new endothelial cell connections . Currently the drug in in Phase II stage of its treatment of Wet Age-Related Macular Degeneration (Wet-AMD).

• BI 836880: Boehringer Ingelheim

BI 836880 is a humanized bispecific nanobody comprising blocking domains for VEGF and angiopoietin-2 (Ang2). BI 836880 is a potent and selective inhibitor of VEGF and Ang2. By binding to VEGF and Ang2, BI 836880 inhibits tumor angiogenesis and vascularization and enhances the tumor microenvironment to support T-cell trafficking and function in the tumor. BI 836880 is currently being investigated in Phase II clinical studies for solid tumors and in Phase I/II clinical studies to treat wet AMD and non-small cell lung cancer.

The Wet AMD Pipeline Report Provides Insights into-

• The report provides detailed insights about companies that are developing therapies for the treatment of Wet AMD with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Wet AMD Treatment.
• Wet AMD Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Wet AMD Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Wet AMD market

Explore groundbreaking therapies and clinical trials in the Wet AMD Pipeline. Access DelveInsight’s detailed report now! @ New Wet AMD Drugs

Wet AMD Companies

Outlook Therapeutics, Opthea, Sylentis, Boehringer Ingelheim, Molecular Partners, Sam Chun Dang Pharm, Generium, Alvotech, Adverum Biotechnologies, EyePoint Pharmaceuticals, 4D Molecular Therapeutics, OliX Pharmaceuticals, Kyowa Kirin, Exonate and others.

Wet Age-related Macular Degeneration pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Wet AMD Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Unveil the future of Wet AMD Treatment. Learn about new drugs, Wet AMD Pipeline developments, and key companies with DelveInsight’s expert analysis @ Wet AMD Market Drivers and Barriers

Scope of the Wet AMD Pipeline Report

• Coverage– Global
• Wet AMD Companies– Outlook Therapeutics, Opthea, Sylentis, Boehringer Ingelheim, Molecular Partners, Sam Chun Dang Pharm, Generium, Alvotech, Adverum Biotechnologies, EyePoint Pharmaceuticals, 4D Molecular Therapeutics, OliX Pharmaceuticals, Kyowa Kirin, Exonate and others.
• Wet AMD Pipeline Therapies- NT-101 0.05 mM, Eylea® (Aflibercept), Intravitreal aflibercept injection, RGX-314, ABP 938, Aflibercept, Ixo-vec, Ranibizumab, and others.
• Wet AMD Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Wet AMD Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Wet AMD Pipeline Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Wet AMD Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Wet Age-related Macular Degeneration: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Wet Age-related Macular Degeneration– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. OPT-302: Opthea
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. SYL1801: Sylentis
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. BI 836880: Boehringer Ingelheim
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Wet Age-Related Macular Degeneration (Wet-AMD) Key Companies
21. Wet Age-Related Macular Degeneration (Wet-AMD) Key Products
22. Wet Age-Related Macular Degeneration (Wet-AMD)- Unmet Needs
23. Wet Age-Related Macular Degeneration (Wet-AMD)- Market Drivers and Barriers
24. Wet Age-Related Macular Degeneration (Wet-AMD)- Future Perspectives and Conclusion
25. Wet Age-Related Macular Degeneration (Wet-AMD) Analyst Views
26. Wet Age-Related Macular Degeneration (Wet-AMD) Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-pipeline-insight